CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 6, 2023-- 2seventy bio, Inc. (NASDAQ: TSVT), (“2seventy” or “the Company”), a leading immuno-oncology cell therapy company, today issued the following statement reiterating its commitment to maximizing shareholder value: As we indicated last month, the Board
PRINCETON, N.J. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 20, 2023-- Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) will meet to review data supporting the supplemental
Abecma (idecabtagene vicleucel) data to be presented at ASH 2023; multiple new analyses of KarMMa-3 and KarMMa-2c add to growing body of data supporting the potential safety and efficacy of Abecma in earlier lines of treatment Abecma generated $69 million U.S.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 10, 2023-- 2seventy bio, Inc . (Nasdaq: TSVT), a leading immune-oncology cell therapy company, will announce its third quarter 2023 financial results on Tuesday, November 14, 2023 . 2seventy bio will host a conference call and webcast at 8:00 a.m.
Approximately 40% workforce reduction combined with related actions expected to achieve $130+ million savings in the 2024-2025 period; projected cash runway into at least 2026 to support focus on long-term mission Company to internally advance fewer pipeline programs while expanding collaboration
Initial MAGE-A4 T-cell collaboration program set to enter clinic ahead of schedule by end of 2023 Companies plan to add programs in oncology and autoimmune disease to collaboration CAMBRIDGE, Mass. & SHANGHAI, China --(BUSINESS WIRE)--Sep. 12, 2023-- 2seventy bio, Inc .
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 6, 2023-- 2seventy bio, Inc . (Nasdaq: TSVT), a leading immune-oncology cell therapy company, announced today that members of the management team will participate in a fireside chat at the upcoming 2023 Morgan Stanley Global Healthcare Conference on
Abecma (idecabtagene vicleucel) generated $115 million U.S. commercial revenue in 2Q 2023, supporting lower end of U.S. revenue guidance of $470-570 million 2seventy bio provides update on PLAT-08 study in AML with partner Seattle Children’s Ended quarter with $307 million cash, cash equivalents,
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 8, 2023-- 2seventy bio, Inc . (Nasdaq: TSVT), a leading immune-oncology cell therapy company, will announce its second quarter 2023 financial results on Monday, August 14, 2023 . 2seventy bio will host a conference call and webcast at 8:00 a.m.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 1, 2023-- 2seventy bio, Inc . (Nasdaq: TSVT), a leading immune-oncology cell therapy company, announced today that members of the management team will present at the upcoming 2023 Wedbush PacGrow Healthcare Conference on August 8, 2023 at 8:00am ET in New